Minimal Residual Disease Market Report 2026

The minimal residual disease market size has grown rapidly in recent years. It will grow from $2.01 billion in 2025 to $2.26 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to rise in leukemia and lymphoma cases, increasing use of flow cytometry testing, early adoption of pcr-based mrd detection, growing clinical focus on relapse prediction, expansion of diagnostic laboratory capabilities.

The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to $3.57 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to rapid growth of ngs-based mrd testing, increasing demand for personalized oncology treatment, development of ultra-sensitive molecular assays, wider adoption of liquid biopsy mrd testing, rising investment in cancer diagnostics research. Major trends in the forecast period include adoption of precision medicine in mrd detection, integration of ai for enhanced sensitivity in mrd testing, expansion of cloud-based data management for mrd monitoring, iot-enabled connectivity in mrd diagnostic platforms, automation and digitalization in laboratory mrd analysis.

The rising prevalence of cancer is expected to drive the growth of the minimal residual disease (MRD) market in the coming years. Cancer comprises a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. Factors contributing to the increasing prevalence of cancer include an aging population, greater exposure to environmental carcinogens, unhealthy lifestyle choices, and genetic predispositions. This rising incidence boosts the demand for accurate MRD testing to detect residual cancer cells, allowing for early intervention and personalized treatment. Such testing improves relapse prediction and enhances patient outcomes. For example, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, over 35 million new cancer cases were projected by 2050, representing a 77% increase from an estimated 20 million cases in 2022. Therefore, the growing prevalence of cancer is propelling the expansion of the MRD market.

Key companies in the MRD market are focusing on the development of ultra-sensitive assays to improve early detection and patient management. Ultra-sensitive assays are laboratory tests designed to identify circulating tumor DNA at extremely low levels with high precision, enabling earlier detection of cancer recurrence and more informed treatment decisions. For instance, in April 2025, Natera, Inc., a US-based provider of cell-free DNA and genetic testing, launched the Signatera Genome MRD test, a personalized, tumor-informed assay built from a patient’s whole genome sequence and matched normal DNA. The test uses multiplex polymerase chain reaction and next-generation sequencing technologies to detect tumor DNA at frequencies as low as 1 part per million. Clinically validated across multiple cancer types - including breast, colorectal, non-small cell lung, melanoma, and renal cell carcinoma - Signatera Genome identifies postsurgical patients at higher risk of recurrence, offers predictive clinical utility, supports both clinical and research applications, and is covered by Medicare across a broad range of indications, enabling more precise and personalized treatment strategies.

In February 2024, Veracyte, Inc., a US-based cancer diagnostics company, acquired C2i Genomics, Inc. for $70 million. This acquisition integrates C2i Genomics’ whole-genome MRD expertise into Veracyte’s diagnostic platform, strengthening its ability to support patients across all stages of cancer care. C2i Genomics, Inc. is a US-based cancer intelligence company providing minimal residual disease testing solutions.

Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., LabCorp, Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Illumina Inc., Personalis Inc., Asuragen Inc., ARUP Laboratories Inc., Myriad Genetics Inc., Luminex Corporation, EntroGen Inc., 3B BlackBio Biotech India, Bioartis, PerkinElmer Inc.

North America was the largest region in the minimal residual disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the minimal residual disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have raised costs for essential diagnostic equipment, reagents, and sequencing technologies used in Minimal Residual Disease (MRD) testing, impacting affordability and accessibility of advanced testing methods. Regions relying heavily on imported molecular diagnostic tools, such as Asia-Pacific and parts of Europe, experience the greatest disruption. Segments like PCR and NGS-based MRD tests are most affected due to dependency on imported kits and instruments. However, tariffs have encouraged domestic production capabilities, stimulating regional manufacturing and reducing long-term supply chain vulnerabilities.

The minimal residual disease market research report is one of a series of new reports that provides minimal residual disease market statistics, including minimal residual disease industry global market size, regional shares, competitors with a minimal residual disease market share, detailed minimal residual disease market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease industry. This minimal residual disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment, even when clinical remission has been achieved. Monitoring MRD helps identify early signs of relapse, assess treatment effectiveness, and predict the likelihood of recurrence. This precise detection enables tailored therapies to improve patient outcomes and reduce the risk of relapse.

The main types of detection targets for minimal residual disease include lymphoma, leukemia, solid tumors, and others. Lymphoma is a cancer that originates in the lymphatic system, primarily affecting white blood cells called lymphocytes. The detection techniques include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, and are utilized by various end users, including banking, financial services, and insurance (BFSI), retail and e-commerce, hospitals, diagnostic laboratories, and research institutions.

The minimal residual disease market consists of revenues earned by entities by providing services such as cancer monitoring, relapse prediction, personalized treatment plans, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimal residual disease market also includes sales of clonality testing kits, MRD detection reagents, and MRD detection panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.